Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 Next >
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host Second Quarter Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Plan to Become a Delaware Corporation
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host First Quarter 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Pricing of $100.0 Million Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Announces Proposed Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.